Inve India ▾

CORONA Remedies share price & results

CORONA Remedies Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

India-centric branded pharma maker of chronic-therapy formulations: cardio-diabetes, women's health, urology.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue422 ₹ crore+21.6% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin22.0 %+2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit60.0 ₹ crore+30.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity31.19 %+1.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin3.99 %−4.3 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)17.96 %−0.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 1 judged target kept · 19 open · verdicts reflect calls analysed to Q1 FY27.

CORONA Remedies Limited management guidance track record on Inve: 20 targets tracked across analysed earnings calls (1 achieved, 0 missed, 19 open).

TargetOriginal wordingSaidLatest callVerdict
Dedicated Infertility Sales TeamLaunch a separate team for infertility... a specialized team of about less than 50 people across the nation within a few months.
Call transcript, Q2 FY26 · 5 Jan 2026		Q2 FY26Q1 FY27:The IVF task force, which started in April 2026, is confirmed to be operational and generating business. Management asks for 2-3 more quarters to provide more details.
Call transcript, Q1 FY27 · 3 Aug 2026		Achieved
R&D Spend as % of RevenueThat percentage will remain less than 2%.
Call transcript, Q2 FY26 · 5 Jan 2026		Q2 FY26Q1 FY27:No specific mention of R&D spend as a percentage of revenue. Strong EBITDA margin improvement to 22% suggests overall cost control, but the specific metric was not addressed.
Call transcript, Q1 FY27 · 3 Aug 2026		At Risk
International Business Revenue ShareIn a couple of years, we can have a CI of around eight, nine percent higher single-digit CI with international business.
Call transcript, Q2 FY26 · 5 Jan 2026		Q2 FY26Q1 FY27:Management reiterated the target of 'higher single-digit' contribution, but extended the timeline to 'three to four years' from now. Current contribution is ~3%.
Call transcript, Q1 FY27 · 3 Aug 2026		Delayed

Source: Inve Guidance Tracker for CORONA Remedies Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

19 of CORONA Remedies Limited's 20 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 17 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,152 +5.42% · +₹110.6

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +53.5% YTD

₹1.4k₹1.6k₹1.8k₹2.0k₹2.2kJanFebMarAprJunJulAugSeptQ2 FY26 — 5 Jan 2026Q3 FY26 — 3 Feb 2026Q4 FY26 — 12 May 2026Q1 FY27 — 3 Aug 2026

YTD: ₹1,402.4 on 1 Jan 2026 → ₹2,152. High ₹2,236.1 (11 Sept 2026), low ₹1,388.3 (21 Jan 2026).

Previous close
₹2,041.4
Market cap
₹12.5k Cr
52-week range
₹1,347.7 – ₹2,236.1
Price to earnings (TTM to Jun 2026)
59.17×
Return on equity (TTM to Jun 2026)
31.19%

Overview

Symbol
NSE:CORONA
Exchange
NSE
Currency
INR

What CORONA Remedies Limited does

Based on the company's own presentations, annual report and earnings calls.

CORONA Remedies is an India-centric branded pharmaceutical formulations company, founded in 2004 and headquartered in Ahmedabad, Gujarat. It develops, manufactures and markets prescription medicines concentrated in chronic and sub-chronic therapy areas — women's healthcare, cardio-diabetes, pain management and urology — marketed mainly to specialist and super-specialist doctors across urban and semi-urban India through its own field force. Revenue is earned overwhelmingly from domestic branded-formulation sales, supplemented by exports to select overseas regulated markets. Manufacturing runs out of two GMP-certified plants in Gujarat and Himachal Pradesh, backed by in-house DSIR-approved R&D facilities, and the brand portfolio has been expanded over the years through in-licensing deals and acquisitions of brands from multinational pharma companies.

Total employees
5,686 (incl. 111 R&D personnel)
Manufacturing facilities
2 (Bhayla, Gujarat and Solan, Himachal Pradesh)
Installed formulation capacity
~1.65 Bn tablets/capsules, 20 Mn sachets, 10 Mn liquid bottles p.a.
Field force strength
4,077
Brand portfolio
76 brands, incl. 32 "Engine" brands
R&D centres
2 DSIR-approved facilities (co-located with plants)
Founded 2004Headquarters Ahmedabad, Gujarat, IndiaEmployees 5,686 (FY2025-26 (Mar-26)) Company website

How the price took the results

close before → close after

Q1 FY27
+0.3%
3 Aug
Q4 FY26
−8.5%
12 May
Q3 FY26
+2.9%
3 Feb
Q2 FY26
+1.6%
5 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for CORONA Remedies Limited

Free account: one company. Everything above stays public.

Write why you follow CORONA Remedies Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse CORONA Remedies Limited

Guides on how to read this kind of business and the numbers that matter.